HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Wyndham H Wilson Selected Research

Cyclophosphamide (Cytoxan)

1/2020Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
1/2019Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
1/2019Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas.
12/2018Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
11/2014Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.
11/2013Low-intensity therapy in adults with Burkitt's lymphoma.
11/2013Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.
4/2013Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.
1/2013Treatment strategies for aggressive lymphomas: what works?
5/2012A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Wyndham H Wilson Research Topics

Disease

48Neoplasms (Cancer)
05/2024 - 06/2002
39Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
04/2024 - 06/2002
30Lymphoma (Lymphomas)
04/2024 - 02/2002
15B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
11/2021 - 09/2002
14B-Cell Lymphoma (Lymphoma, B Cell)
12/2021 - 02/2002
12Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
01/2022 - 09/2005
8Burkitt Lymphoma (Burkitt's Lymphoma)
04/2024 - 06/2006
6Neutropenia
05/2023 - 08/2005
6Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2016 - 08/2005
5Hairy Cell Leukemia
01/2018 - 11/2004
5Disease Progression
05/2015 - 09/2004
4Infections
05/2023 - 06/2009
4Leukemia
01/2020 - 09/2009
4Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
08/2014 - 11/2004
4Hemolytic-Uremic Syndrome
05/2012 - 09/2005
4Acquired Immunodeficiency Syndrome (AIDS)
03/2012 - 06/2003
4Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
11/2010 - 02/2006
3Lymphopenia (Lymphocytopenia)
05/2023 - 12/2010
3Thrombocytopenia (Thrombopenia)
01/2023 - 09/2002
3Residual Neoplasm
01/2022 - 12/2021
3Hodgkin Disease (Hodgkin's Disease)
01/2019 - 08/2010
3AIDS-Related Lymphoma (Lymphoma, AIDS Related)
11/2014 - 04/2006
2Aspergillosis
05/2024 - 12/2017
2Febrile Neutropenia
01/2023 - 01/2021
2Inflammation (Inflammations)
01/2020 - 01/2011
2Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
01/2018 - 12/2010
2Multiple Myeloma
10/2017 - 10/2010
2Hematologic Neoplasms (Hematological Malignancy)
09/2014 - 06/2011
2Hypoalbuminemia
05/2012 - 09/2005
2Fatigue
05/2012 - 09/2005
2Edema (Dropsy)
05/2012 - 09/2005
2T-Cell Lymphoma (Lymphoma, T Cell)
02/2011 - 07/2007
2Lymphoproliferative Disorders (Lymphoproliferative Disorder)
10/2010 - 02/2006
2Pneumonia (Pneumonitis)
05/2010 - 12/2004
2Opportunistic Infections (Opportunistic Infection)
04/2010 - 07/2006
1Leukopenia
05/2023
1Lymphomatoid Granulomatosis (Granulomatosis, Lymphomatoid)
05/2023
1Anemia
01/2021
1COVID-19
01/2020
1Adenocarcinoma
01/2019

Drug/Important Bio-Agent (IBA)

28Rituximab (Mabthera)FDA Link
01/2020 - 02/2002
17Doxorubicin (Adriamycin)FDA LinkGeneric
01/2023 - 02/2002
17Vincristine (Oncovin)FDA LinkGeneric
01/2020 - 02/2002
17Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2020 - 02/2002
17Prednisone (Sone)FDA LinkGeneric
01/2020 - 02/2002
16Etoposide (VP 16)FDA LinkGeneric
01/2020 - 02/2002
11Biomarkers (Surrogate Marker)IBA
01/2022 - 06/2007
9Circulating Tumor DNAIBA
11/2022 - 01/2016
7ibrutinibIBA
12/2021 - 08/2015
6Proteins (Proteins, Gene)FDA Link
01/2023 - 12/2005
6Monoclonal AntibodiesIBA
01/2018 - 02/2002
6Cyclin D1IBA
11/2013 - 02/2003
5DNA (Deoxyribonucleic Acid)IBA
12/2021 - 06/2002
5fludarabineIBA
08/2013 - 09/2002
4Agammaglobulinaemia Tyrosine KinaseIBA
05/2024 - 12/2017
4Bortezomib (Velcade)FDA Link
09/2015 - 06/2009
4Anaplastic Lymphoma KinaseIBA
08/2014 - 11/2004
4Immunotoxins (Immunotoxin)IBA
05/2012 - 09/2005
3Immunoglobulins (Immunoglobulin)IBA
01/2022 - 10/2010
3Lenalidomide (CC 5013)FDA Link
01/2021 - 09/2009
3immunotoxin HA22IBA
01/2018 - 06/2011
3Transaminases (Aminotransferases)IBA
05/2012 - 09/2005
3Chimeric Antigen ReceptorsIBA
03/2012 - 09/2009
3AntigensIBA
09/2009 - 09/2005
2Indicators and Reagents (Reagents)IBA
01/2023 - 09/2011
2AnthracyclinesIBA
01/2022 - 12/2010
2navitoclaxIBA
01/2021 - 12/2010
2Cyclin-Dependent Kinases (cdk Proteins)IBA
12/2019 - 03/2010
2Alemtuzumab (Campath)FDA Link
01/2019 - 06/2004
2AntibodiesIBA
01/2019 - 01/2011
2Janus KinasesIBA
09/2014 - 02/2013
2CytokinesIBA
03/2012 - 09/2009
2NF-kappa B (NF-kB)IBA
01/2011 - 06/2006
2Messenger RNA (mRNA)IBA
06/2007 - 02/2003
1Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA
04/2024
1GlucocorticoidsIBA
04/2024
1src-Family KinasesIBA
04/2024
1Interferon alpha-2 (Roferon-A)FDA Link
05/2023
1BilirubinIBA
01/2023
1Complement System Proteins (Complement)IBA
11/2022
1Cell-Free Nucleic AcidsIBA
12/2021
1Phospholipases (Phospholipase)IBA
11/2021
1C-Reactive ProteinIBA
01/2020
1Oxygen (Dioxygen)IBA
01/2020
1Interleukin-6 (Interleukin 6)IBA
01/2020
1acalabrutinibIBA
01/2020
1alvocidib (flavopiridol)IBA
12/2019
1Immunoglobulin Variable RegionIBA
01/2019
1Cytidine DeaminaseIBA
01/2019

Therapy/Procedure

38Therapeutics
11/2022 - 04/2002
29Drug Therapy (Chemotherapy)
05/2023 - 02/2002
4Precision Medicine
11/2022 - 01/2019
3Highly Active Antiretroviral Therapy (HAART)
04/2012 - 06/2003
2Radiotherapy
01/2018 - 04/2013
2Hematopoietic Stem Cell Transplantation
03/2012 - 03/2003
2Immunotherapy
03/2012 - 03/2008
2Transplantation
03/2012 - 03/2003
2Aftercare (After-Treatment)
04/2010 - 10/2005
2Plasmapheresis
06/2009 - 09/2005
1Artificial Respiration (Mechanical Ventilation)
01/2020